Figure Legends:
Figure 1. The course of CRP, ferritin, and lymphocyte values on 1st, 3rd, and 5 the days in COVID-19.
REFERENCES:
  1. COVID-19 Map. [cited March 28,2021]. Available from: https://coronavirus.jhu.edu/ map.html
  2. L.H. Calabrese, Cytokine storm and the prospects for immunotherapy with COVID19, Cleve. Clin. J. Med. 87 (7) (2020 May 11) 389–393, https://doi.org/10.3949/ ccjm.87a.ccc008, pii: ccc008, Published 2020 Jun 30.
  3. Lam, C.W., Chan, M.H., Wong, C.K., 2004. Severe acute respiratory syndrome: clinical and laboratory manifestations. Clin. Biochem. Rev. 25, 121–132.
  4. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with covid-19-preliminary report. New Engl. J. Med.2021;384:693-704. DOI:10.1056/ NEJMoa2021436
  5. Sauñe, Patricia & Bryce-Alberti, Mayte & Portmann-Baracco, Arianna & Accinelli, Roberto. (2020). Methylprednisolone pulse therapy: An alternative management of severe COVID-19. Respiratory medicine case reports. 31.101221.10.1016/j.rmcr.2020. 101221.
  6. Bhimraj A., Morgan L., R.L Shumaker, A.H., Lavergne, V., Baden, L., Cheng, V et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Published by IDSA on 3/02/2021. Last updated February 3, 2021, www.idsociety.org/COVID19guidelines.
  7. World Health Organization (WHO), 2020. Coronavirus Disease (COVID-19) Situation Dashboard. (Accessed June 28, 2020). https://www.who.int/emergencies/diseases/ novel-coronavirus-2019.
  8. Ministry of Health, General Directorate of Public Health. COVID-19 (SARS-CoV-2 Infection) Adult Patient Treatment Scientific Advisory Board Study, October 9, 2020.
  9. Tobaiqy M, Qashqary M, Al-Dahery S, et al. Therapeutic management of patients with COVID-19: a systematic review. Infection Prevention in Practice. 2020;2(3):100061. doi:10.1016/j.infpip.2020.100061
  10. Pagliano P, Scarpati G, Sellitto C, Conti V, Spera AM, Ascione T, Piazza O, Filippelli A. Experimental Pharmacotherapy for COVID-19: The Latest Advances. J Exp Pharmacol. 2021 Jan 7;13:1-13. doi: 10.2147/JEP.S255209. PMID: 33442304; PMCID: PMC7800714.
  11. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine & Growth Factor Reviews. 2020;53:38–42. DOI: 10.1016/j.cytogfr.2020.04.002
  12. Mattos-Silva, P., Felix, N. S., Silva, P. L., Robba, C., Battaglini, D., Pelosi, P., et al. Pros and cons of corticosteroid therapy for COVID-19 patients.  Respir Physiol Neurobiol. 2020;280:103492. doi:10.1016/j.resp.2020.103492
  13. Kolilekas L, Loverdos K, Giannakaki S, et al. Can steroids reverse the severe COVID-19 induced ‘cytokine storm’? J Med Virol. 2020;92 (11):2866–2869.
  14. So C, Ro S, Murakami M, Imai R, Jinta T. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series. Respirol Case Rep. 2020;8(6):e00596. Published 2020 Jun 4. doi:10.1002/rcr2.596
  15. Chen Q, Song Y, Wang L, et al. Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study [published online ahead of print, 2021 Feb 1]. Expert Rev Respir Med. 2021;1-10. doi:10.1080/17476348.2021.1856659
  16. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020 March-April,;34(2):327-331. doi: 10.23812/CONTI-E. PMID: 32171193.
  17. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683-684. doi:10.1016/S0140-6736(20)30361-5
  18. Dai J, Xiong Y, Li H, et al. Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review. Clin Rheumatol. 2020;39(7):2031–2037
  19. Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med (Lausanne). 2020;7:170.
  20. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B et al. High– Dose Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute Respiratory Syndrome. American Journal of Respiratory and Critical Care Medicine. 2003;168(12):1449–56. DOI: 10.1164/rccm.200306-766OC
  21. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475.
  22. Bartoletti M, Marconi L, Scudeller L, Pancaldi L, Tedeschi S, Giannella M, et al,PREDICO Study Group. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. Clin Microbiol Infect. 2021 Jan;27(1):105-111. doi: 10.1016/j.cmi.2020.09.014. Epub 2020 Sep 22. PMID: 32971254; PMCID: PMC7506332.
  23. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943. doi:10.1001/jamainternmed.2020.0994
  24. Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, Rajagopal S, et al. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol. 2020 Jul 10;11:1648. doi: 10.3389/fimmu.2020.01648. PMID: 32754159; PMCID: PMC7365905.